Lv7
4076 积分 2021-01-24 加入
Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network
3天前
求助中
Phase II Trial of Gemcitabine and nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation
3天前
已完结
ABI 007
4天前
已完结
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
5天前
已完结
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial
12天前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
22天前
已完结
First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
26天前
已完结
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study
26天前
已完结
Zanidatamab: First Approval
27天前
已完结
Margetuximab and trastuzumab deruxtecan: New generation of anti-HER2 immunotherapeutic agents for breast cancer
1个月前
已完结
皖公网安备34019202002308
